Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568034 | 0.84 | DAO (0.49) | DAOCA12CA9KDM4EALDH1A1 | |
| SCHEMBL21959783 | 0.82 | KDM4E (0.60) | LOXL2PIN1DAOCA12CA9 | |
| SCHEMBL23506812 | 0.80 | PIN1 (0.46) | LOXL2PIN1DAOCA12CA9 | |
| SCHEMBL17030633 | 0.80 | LOXL2 (0.47) | LOXL2PIN1DAOCA12CA9 | |
| SCHEMBL3434958 | 0.80 | KIF11 (0.46) | ALDH1A1HPGDHSD17B10ALOX15CYP2A6 | |
| SCHEMBL31276626 | 0.80 | KIF11 (0.46) | ALDH1A1HPGDHSD17B10ALOX15CYP2A6 | |
| SCHEMBL13923569 | 0.80 | LOXL2 (0.50) | LOXL2DAOKDM4EALDH1A1HPGD | |
| SCHEMBL23836917 | 0.79 | LOXL2 (0.46) | LOXL2PIN1DAOCA12CA9 | |
| SCHEMBL75581 | 0.79 | CYP2A6 (0.63) | LOXL2PIN1DAOCA12CA9 | |
| SCHEMBL29727931 | 0.79 | CYP2A6 (0.63) | LOXL2PIN1DAOCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20230312511-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2023-10-05 | — | — | US | disclosed |
| US-20230312511-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2023-10-05 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| EP-3675847-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-27 | — | — | US | disclosed |
| US-20210323941-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNIVERSITY OF KANSAS | 2021-10-21 | — | — | US | disclosed |
| US-11142526-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-10-12 | — | — | US | disclosed |
| US-8575209-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-8415387-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-09 | — | — | US | disclosed |
| US-8153784-B2 | Imaging of enzyme activity | THE GENERAL HOSPITAL CORPORATION (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080044827-A1 | Imaging of Enzyme Activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-02-21 | — | — | US | disclosed |
| WO-2007117715-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323941-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | SLC6A3, DRD3, CHRM2 | LOXL2 3690/4885PIN1 4745/4885DAO 1368/4885 |
| US-20080044827-A1 | Imaging of Enzyme Activity | GBA3, BCHE, MGAM | LOXL2 1906/4885PIN1 1048/4885DAO 168/4885 |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | LOXL2 4511/4885PIN1 346/4885DAO 3038/4885 |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | LOXL2 2119/4885PIN1 2293/4885DAO 3031/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | LOXL2 4691/4885PIN1 70/4885DAO 69/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | LOXL2 4467/4885PIN1 715/4885DAO 173/4885 |
| US-20230312511-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | SLC6A3, DRD3, DRD2 | LOXL2 3936/4885PIN1 4719/4885DAO 1418/4885 |
| US-11142526-B2 | Spirocycle compounds and methods of making and using same | OPRL1, MGLL, OPRK1 | LOXL2 459/4885PIN1 1174/4885DAO 3758/4885 |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | LOXL2 3949/4885PIN1 3215/4885DAO 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.